132 related articles for article (PubMed ID: 16615041)
1. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
2. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
3. [Protein expressions of matrix metalloproteinase-9 and its inhibitor and their ratio changes in wound healing of patients with stages Ⅲ and Ⅳ pressure ulcers].
Wang Y; Li X; Zhao W; Gao ZZ; Zheng MJ; Pang YL; Chen ZY
Zhonghua Shao Shang Za Zhi; 2019 Oct; 35(10):746-751. PubMed ID: 31658546
[No Abstract] [Full Text] [Related]
4. The serum levels of circulating matrix metalloproteinase MMP-9, MMP-2/TIMP-2 complex and TIMP-1 do not change significantly during normal pregnancy: a pilot study.
Nissi R; Santala M; Talvensaari-Mattila A
BMC Res Notes; 2021 Jan; 14(1):31. PubMed ID: 33482846
[TBL] [Abstract][Full Text] [Related]
5. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.
Raeeszadeh-Sarmazdeh M; Greene KA; Sankaran B; Downey GP; Radisky DC; Radisky ES
J Biol Chem; 2019 Jun; 294(24):9476-9488. PubMed ID: 31040180
[TBL] [Abstract][Full Text] [Related]
6. Expressions of Matrix Metalloproteinases-9 and Tissue Inhibitor of Metalloproteinase-1 in Pituitary Adenomas and Their Relationships with Prognosis.
Guo H; Sun Z; Wei J; Xiang Y; Qiu L; Guo L; Zhao W; Xu Z; Mao J
Cancer Biother Radiopharm; 2019 Feb; 34(1):1-6. PubMed ID: 30676069
[TBL] [Abstract][Full Text] [Related]
7. Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma.
Matulka M; Konopka A; Mroczko B; Pryczynicz A; Kemona A; Groblewska M; Sieskiewicz A; Olszewska E
Dis Markers; 2019; 2019():3136792. PubMed ID: 31143300
[TBL] [Abstract][Full Text] [Related]
8. MMP-9 and MMP-2 regulation in patients undergoing non-oncological and non-vascular elective surgery independent of the use of propofol or sevoflurane.
Kowalczyk M; Guz M; Okoń E; Jeleniewicz W; Grzycka-Kowalczyk L; Kiełbus M; Dudka J; Suseł W; Dąbrowski W; Stepulak A
Pharmacol Rep; 2019 Jun; 71(3):528-534. PubMed ID: 31015093
[TBL] [Abstract][Full Text] [Related]
9. Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function.
Adamidis KN; Kopaka ME; Petraki C; Charitaki E; Apostolou T; Christodoulidou C; Nikolopoulou N; Giatromanolaki A; Vargemesis V; Passadakis P
Ren Fail; 2019 Nov; 41(1):229-237. PubMed ID: 30973283
[TBL] [Abstract][Full Text] [Related]
10. The Activity of Matrix Metalloproteinases (MMP-2, MMP-9) and Their Tissue Inhibitors (TIMP-1, TIMP-3) in the Cerebral Cortex and Hippocampus in Experimental Acanthamoebiasis.
Łanocha-Arendarczyk N; Baranowska-Bosiacka I; Gutowska I; Kolasa-Wołosiuk A; Kot K; Łanocha A; Metryka E; Wiszniewska B; Chlubek D; Kosik-Bogacka D
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572657
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.
Huang X; Lan Y; Li E; Li J; Deng Q; Deng X
J Int Med Res; 2021 May; 49(5):3000605211012570. PubMed ID: 33942633
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and immunohistochemical analysis of tissue inhibitor of metalloproteinases-1 in human sound dentin.
Gobbi P; Maravic T; Comba A; Mazzitelli C; Mancuso E; Falconi M; Breschi L; Mazzoni A
Clin Oral Investig; 2021 Aug; 25(8):5067-5075. PubMed ID: 33569677
[TBL] [Abstract][Full Text] [Related]
13. Tissue Inhibitor of Metalloproteinase-1 Promotes Polymorphonuclear Neutrophil (PMN) Pericellular Proteolysis by Anchoring Matrix Metalloproteinase-8 and -9 to PMN Surfaces.
Wang X; Rojas-Quintero J; Wilder J; Tesfaigzi Y; Zhang D; Owen CA
J Immunol; 2019 Jun; 202(11):3267-3281. PubMed ID: 31019060
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer.
Zhang Y; Qin L; Ma X; Wang Y; Wu Y; Jiang J
Dis Markers; 2020; 2020():8831466. PubMed ID: 33005257
[TBL] [Abstract][Full Text] [Related]
15. TIMP-2 inhibits metastasis and predicts prognosis of colorectal cancer via regulating MMP-9.
Wang W; Li D; Xiang L; Lv M; Tao L; Ni T; Deng J; Gu X; Masatara S; Liu Y; Zhou Y
Cell Adh Migr; 2019 Dec; 13(1):273-284. PubMed ID: 31293204
[TBL] [Abstract][Full Text] [Related]
16. Plasma Levels of MMPs and TIMP-1 in Patients with Osteoarthritis After Recovery from COVID-19.
Tuharov Y; Krenytska D; Halenova T; Kot L; Raksha N; Savchuk O; Prysiazhniuk L; Matkivska R; Falalyeyeva T; Ostapchenko L
Rev Recent Clin Trials; 2023; 18(2):123-128. PubMed ID: 37231778
[TBL] [Abstract][Full Text] [Related]
17. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
Hosseini A; Kumar S; Hedin K; Raeeszadeh-Sarmazdeh M
Protein Sci; 2023 Dec; 32(12):e4795. PubMed ID: 37807423
[TBL] [Abstract][Full Text] [Related]
18. Engineering of tissue inhibitor of metalloproteinases TIMP-1 for fine discrimination between closely related stromelysins MMP-3 and MMP-10.
Raeeszadeh-Sarmazdeh M; Coban M; Mahajan S; Hockla A; Sankaran B; Downey GP; Radisky DC; Radisky ES
J Biol Chem; 2022 Mar; 298(3):101654. PubMed ID: 35101440
[TBL] [Abstract][Full Text] [Related]
19. A potential key mechanism in ascending aortic aneurysm development: Detection of a linear relationship between MMP-14/TIMP-2 ratio and active MMP-2.
Schmitt R; Tscheuschler A; Laschinski P; Uffelmann X; Discher P; Fuchs J; Kreibich M; Peyronnet R; Kari FA
PLoS One; 2019; 14(2):e0212859. PubMed ID: 30794673
[TBL] [Abstract][Full Text] [Related]
20. miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
Ivanovic RF; Viana NI; Morais DR; Moura C; Silva IA; Leite KR; Pontes-Junior J; Nahas WC; Srougi M; Reis ST
BMC Cancer; 2018 Oct; 18(1):992. PubMed ID: 30340564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
